-
Correction to “Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis” Dermatol. Ther. (IF 3.7) Pub Date : 2022-12-05
Li J, Wang J, Li D, et al. Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: a retrospective cohort analysis. Dermatologic Therapy. 2021;34(5):e15067. Some of the funding information was incorrect. Guangzhou Health and Family Planning Commission Technology Project (20191A1515011263) should have been Guangdong Basic and Applied Basic Research
-
A case report of vitiligo following toripalimab therapy for a patient with metastatic melanoma. Dermatol. Ther. (IF 3.7) Pub Date : 2022-11-16 Yihao Li,Min Zhang,Hongbin Zhou,Kelei Zhao,Xiaohan Yuan,Yanting Liu,Ping Lu
-
A case of erythema nodosum concomitant with ulcerative colitis relieved by tofacitinib. Dermatol. Ther. (IF 3.7) Pub Date : 2022-11-10 Kanae Nakamura,Emi Sato,Shinichi Imafuku
-
Cutaneous lupus erythematosus variants responsive to Janus kinase inhibition. Dermatol. Ther. (IF 3.7) Pub Date : 2022-11-22 Lokapriya Ananthan,Megan Williams,Huw Morgan,Girish K Patel
-
Comprehensive treatment of basal cell carcinoma in nevoid basal cell carcinoma syndrome with 5-fluorouracil and salicylic acid. Dermatol. Ther. (IF 3.7) Pub Date : 2022-11-16 Yangyiyi Yu,Guiying Zhang,Siqi Fu
-
Efficacy and safety of date palm leaf-based ointment for treatment of cutaneous warts: A pilot clinical trial Dermatol. Ther. (IF 3.7) Pub Date : 2022-11-08 Azin Ayatollahi, Nima Aramipour, Arash Sadri, Alireza Firooz, Reza M. Robati, Mahsa Fattahi, Masoud Ayazi, Mohammad Saber
Despite the considerably high prevalence of cutaneous warts, no optimally effective and safe treatment is available. Leaves of date palm (Phoenix dactylifera L.; Arecaceae) have long been used in Iran's folk medicine as a remedy for warts. To assess the state-of-the-art evidence on using P. dactylifera L. for warts, we conducted a systematic review using CINAHL (via EBSCO), Embase, Medline (via PubMed)
-
Simvastatin and non-segmental vitiligo: A new potential treatment option? Dermatol. Ther. (IF 3.7) Pub Date : 2022-11-08 Engi Seif E. Shaker, Sherihan H. Allam, Maaly M. Mabrouk, Nashwa M. Elgharbawy, Shady Fikry Abdel Salaam
There is a paucity of data about the impact of systemic statins on vitiliginous lesions in non-segmental vitiligo (NSV) patients. To the best of our knowledge, no other studies have considered the correlation between lipid disturbances in vitiligo and vitiligo disease activity (VIDA) score. We sought in this study to evaluate the influence of simvastatin on vitiliginous lesions in NSV patients with
-
Comparison of 1064 nm Q-switched Nd:YAG laser and Jessner peeling in melasma treatment Dermatol. Ther. (IF 3.7) Pub Date : 2022-11-08 Ilgen Ertam Sagduyu, Onur Marakli, Gokturk Oraloglu, Ecem Bulut Okut, Idil Unal
Melasma is an acquired hyperpigmentation disease characterized by hyperpigmented patches in sun-exposed areas that significantly impairs life quality. Topical treatments such as hydroquinone, retinoic acid, azelaic acid, chemical peels and laser treatments are among the main treatment options. In our study, we aimed to compare the effectiveness of Jessner peeling and 1064 nm Q-switched Nd:YAG laser
-
Evaluation of the efficacy and relapse rates of treatment protocols for moderate acne using isotretinoin based on the global acne grading system: Randomized, controlled, comparative study Dermatol. Ther. (IF 3.7) Pub Date : 2022-11-08 Bushra Kassem, Mohammad Ismail, Fouz Hassan
Protocols for treating acne with isotretinoin have varied widely because some factors associated with relapse and treatment duration have not yet been fully determined. This paper evaluates the effectiveness of conventional, low, and intermittent isotretinoin dosage protocols in the treatment of moderate acne and investigates the relationships between GAGS score, treatment duration and relapse rate
-
High versus low dose oral isotretinoin in the treatment of cutaneous and genital warts Dermatol. Ther. (IF 3.7) Pub Date : 2022-11-08 Ahmad Nofal, Mohamed M. Fawzy, Fatma Eldeeb, Hager Nofal, Esraa E. El-Hawary
Although oral isotretinoin has been considered as a potential therapeutic option for the treatment of different types of warts, the optimum dosage regimen is not yet well-established. To evaluate the efficacy and adverse effects of high versus low doses of oral isotretinoin in the treatment of cutaneous and genital warts. The study included 100 patients who were randomly assigned to two groups, 50
-
Melanoma surgery—An update Dermatol. Ther. (IF 3.7) Pub Date : 2022-11-06 Uwe Wollina
Cutaneous melanoma is the major cause of mortality from all skin cancers. The treatment has been revolutionized in recent years by introduction of immunotherapy and targeted therapy for melanoma patients Stages III and IV. Therefore, the role of surgery in melanoma treatment needs to be redefined. In this narrative review, we will focus on surgery for diagnosis, treatment of primary tumor, and metastases
-
Investigating the efficacy and safety of calcipotriol/betamethasone dipropionate foam and laser microporation for psoriatic nail disease—A hybrid trial using a smartphone application, optical coherence tomography, and patient-reported outcome measures Dermatol. Ther. (IF 3.7) Pub Date : 2022-11-02 Vinzent Kevin Ortner, Victor Desmond Mandel, Kresten Skak, John Robert Zibert, Mélanie Bourlioux, Christoffer Valdemar Nissen, Christine Sofie Krohn Fuchs, Peter Alshede Philipsen, Merete Haedersdal
There is a lack of efficacious topical treatments for patients suffering from psoriatic nail disease (PND). We investigated the efficacy of Calcipotriol-Betamethasone Dipropionate (Cal/BD) foam with and without ablative fractional laser (AFL) in patients with PND. A total of 144 nails from 11 patients were treated in a 24-week long, open-label, randomized, intra-patient controlled proof-of-concept
-
Bullous pilomatricoma arising at a COVID-19 vaccination site. Dermatol. Ther. (IF 3.7) Pub Date : 2022-11-01 Bingfeng Zheng,Shaoyuan Wang,Chunshan Li
-
Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-26 Manuel Agud-Dios, Jorge Arroyo-Andres, Carmen Rubio-Muñiz, Carlos Zarco-Olivo, Alba Calleja-Algarra, Jaime de Inocencio, Sara Isabel Palencia Perez
A 5-year-old Romanian boy presented with heliotrope erythema, periungual telangiectasia, Gottron's papules, discrete calcium deposits over extensor surfaces and severe myositis. Whole-body magnetic resonance revealed bilateral generalized myositis and he was diagnosed with juvenile dermatomyositis. Esophagogram, cardiac and pulmonary evaluation and myositis-specific autoantibodies were normal. He received
-
Is cysteamine use effective in the treatment of melasma? A systematic review and meta-analysis Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-25 Agenor Gomes dos Santos-Neto, Ísis Carolline Valério da Silva, Carlisson Ramos Melo, Adilson Allef Moraes Santana, Ricardo Luiz Cavalcanti de Albuquerque-Junior
Melasma is a recurrent hypermelanosis disorder characterized by the appearance of brownish and symmetrical spots on the skin. It affects the quality of life and is resistant to available treatment approaches. Cysteamine has been reported as a promising depigmenting agent for melasma treatment and following formulation enhancement, its use is being reported. This review aimed to evaluate the efficacy
-
Real-world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-24 Pravit Asawanonda, Bensachee Pattamadilok, Leena Chularojanamontri, Mati Chuamanochan, Charoen Choonhakarn, Panlop Chakkavittumrong, Naruemon Sangob, Natta Rajatanavin
Secukinumab demonstrated high efficacy and favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) in clinical trials. However, understanding of patient characteristics and clinical outcomes in real world in Thailand is still limited. To describe patient characteristics, effectiveness and safety of secukinumab in Thai PsO patients. This retrospective study analyzed data
-
Benvitimod for the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-24 Muhammad Ehsan, Aqeeb Ur Rehman, Farwa Athar, Biah Mustafa, Haseeba Javed, Huzaifa Ahmad Cheema, Muhammad Ayyan, Abia Shahid, Uzair Jafar, Mohamad Goldust
Benvitimod is a topical drug that has recently been approved for mild to moderate psoriasis and atopic dermatitis. The drug has just completed phase 3 trials for psoriasis, which calls for a systematic update of current evidence on the efficacy and safety of this drug. We searched MEDLINE (PubMed), EMBASE, Science Direct, International Clinical Trials Registry Platform (ICTRP), Cochrane Central Register
-
Long lasting response to anti-tumor necrosis factor α agents in psoriasis: A real life experience Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-22 Maria Letizia Musumeci, Andrea Calogero Trecarichi, Giuliana Caruso, Alice Aleo, Helga Platania, Giuseppe Micali
Psoriasis is a chronic, immune-mediated inflammatory disease for which no definitive cure exists and patients difficult to treat with moderate to severe psoriasis often require life-long therapy. In general, the use of any biologic agent as monotherapy allows a long-term efficacy, however survival response may progressively decrease over time. We report real-world long lasting response data in psoriatic
-
Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real-world experience Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-22 Melis Gönülal, İlknur Kıvanç Altunay, Sinan Doğan, Meltem Türkmen, Didem Didar Balcı, Serap Öztürkcan
Real-life data about any particular treatment is very helpful for clinicians, particularly when managing a chronic disease such as psoriasis. In our study, we aimed to reflect our clinical experience during 48 weeks with an IL-17 antagonist ixekizumab. This study was designed as a retrospective multi-center study. Four tertiary referral centers participated into the study. The patients who did not
-
A case of atopic dermatitis-associated dupilumab-resistant alopecia totalis successfully treated with baricitinib. Dermatol. Ther. (IF 3.7) Pub Date : 2022-11-01 Takashi Seo,Kentaro Izumi,Takuya Kawamura,Masumi Tsujiwaki,Hideyuki Ujiie
-
Sharpen your sight: Trombiculosis under the dermatoscope with LC-OCT new insights. Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-31 Simone Cappilli,Enrico Bocchino,Luigi Cornacchia,Ketty Peris,Alessandro Di Stefani
-
Sub-erythrodermic psoriasis successfully treated with bimekizumab: A case report Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-21 Mario Valenti, Luigi Gargiulo, Luciano Ibba, Giulia Pavia, Alessandra Narcisi, Antonio Costanzo
Erythrodermic psoriasis (EP) is a rare variant of psoriasis, accounting for 1%–2% of all cases of plaque psoriasis.1 EP is characterized by generalized erythema and scaling affecting more than 75% of body surface area, with or without systemic symptoms.1 Due to both the rarity and the severity of this condition, which make it difficult to carry out randomized controlled clinical trials, the treatment
-
Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomes Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-21 Eric Simpson, April Armstrong, Mark Boguniewicz, Zelma C. Chiesa Fuxench, Meghan Feely, Evangeline Pierce, Luna Sun, Yun-Fei Chen, Robinette Angle, Jonathan I. Silverberg
To address the need for long-term efficacy and patient-reported outcomes (PROs) data for patients with atopic dermatitis (AD) treated with baricitinib 2 mg, a study was conducted to evaluate the efficacy of baricitinib 2 mg in adult patients with moderate-to-severe AD. Data presented here provided efficacy and outcomes data for patients treated for 52 weeks. Patients who participated in the originating
-
Variation of body regional responses to Ustekinumab and Secukinumab in psoriasis patients: A real-world retrospective study and literature review Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-20 Pai-Shan Cheng, Ping-Chen Hou, Chao-Chun Yang, Chia-Bao Chu
Psoriasis in different body regions displays varying therapeutic responses to biologics, whereas currently relevant studies remain scarce. We retrospectively reviewed the treatment responses of patients with moderate-to-severe psoriasis, who completed the two-year reimbursed ustekinumab or secukinumab treatment in two medical centers in Southern Taiwan. Demographic profiles and body regional PASI scores
-
Intravenous immunoglobulin for pembrolizumab-induced bullous pemphigoid-like eruption: A case report. Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-31 Daichi Hoshina,Moeko Hotta
-
Fatal low-dose methotrexate toxicity: A case report and literature review Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-19 Samantha Ouellette, Rohan Shah, Shazli Razi, Gina Ashforth, Cindy Wassef
Methotrexate (MTX) is a chemotherapeutic agent that acts primarily by inhibiting the folic acid cycle. In addition to its application for treating malignancies, MTX is also used to treat chronic inflammatory diseases including psoriasis. Adverse effects have been reported even at low doses (up to 25 mg/week), and there is risk of toxicity in the form of myelosuppression, hepatotoxicity, or pulmonary
-
Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-19 Camilla Vassallo, Anita Somenzi, Mara De Amici, Stefania Barruscotti, Valeria Brazzelli
Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease, characterized by the development of autoantibodies against hemidesmosomal components BP180 and BP230. The mainstay of therapy is topical and systemic corticosteroids (CS) and immunosuppressors. As this pathology mainly involves the elderly, subjects often have numerous comorbidities that influence the clinical management
-
Intravenous immunoglobulin therapy in children with severe atopic dermatitis Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-19 Zhen Zhang, Jiawen Chen, Yijun Yang, Ruoqu Wei, Peiyi Sun, Wenqing Zhang, Wange Zhou, Yifeng Guo, Zhirong Yao
Children with severe atopic dermatitis (AD) can benefit from intravenous immunoglobulin (IVIG) therapy. This study aimed to identify the efficacy and safety of IVIG therapy in children with severe AD. Twenty pediatric AD patients were enrolled in this study. Patients with an Investigator's Global Assessment score of 0 or 1 or a reduction of 2 points after treatment were defined as high-responders (HRs)
-
Influence of serum vitamin D level in the response of actinic keratosis to ingenol mebutate Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-19 Ricardo Moreno-Alonso de Celada, Tamara Gracia-Cazaña, Laura Najera-Botello, Paulina Cerro-Muñoz, Angeles Juarranz, Salvador Gonzalez, Yolanda Gilaberte
Vitamin D (VD) serum levels, and keratinocytic basal expression of vitamin D receptor (VDR) before treatment of actinic keratoses (AK) have been previously reported as possible biomarkers of the response of AK to treatments. We intended to evaluate the association between these and other serum and immunohistochemical parameters with the response of AK to treatment with topical ingenol mebutate (IM)
-
Leucocytoclastic vasculitis-like reaction induced by tocilizumab in a patient with rheumatoid arthritis. Dermatol. Ther. (IF 3.7) Pub Date : 2022-11-15 Yu-Qing Hu,Xue Chen,Jian-Zhong Zhang
-
Bullous lichen sclerosus–generalized morphea overlap syndrome improved by tofacitinib Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-18 Licong Liu, Yi Zhan, Yaqian Shi, Zhuotong Zeng, Jiangfan Yu, Puyu Zou, Xiangning Qiu, Ying Zhou, Guiying Zhang, Yan Ding, Rong Xiao
We here report a case of a middle-aged man with an unusual case of bullous lichen sclerosus complicated with generalized morphea. He showed initial recurrent flaccid bullae, followed by ivory-white sclerotic plaques and extensive skin sclerosis, with additional walking disorder caused by knee-joint contracture, and ulcers on the lower extremities and back. The patient had no visceral involvement. After
-
Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-18 Mohammadreza Ghassemi, Nafise Yazdanian, Elham Behrangi, Mohammadamin Jafari, Azadeh Goodarzi
Alopecia areata (AA), a polygenic and chronic autoimmune disease and there is no definitive cure. We aimed to evaluate latanoprost effects in patients with AA. In this controlled randomized double-blind clinical trial, we enrolled patients with AA randomly assigned to six groups of 18; Group 1 received latanoprost eye drops; group 2 minoxidil 5% solution; group 3 latanoprost eye drops and minoxidil
-
Treatment of atopic dermatitis using topical antifungal drugs: A meta-analysis Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-18 Dan He, Yujie Han, Hongmei Wu, Min Liu, Mao Li, Mao Lu
Several studies have focused on treating atopic dermatitis (AD) using topical antifungal drugs. However, their findings are inconsistent. This meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the safety and efficacy of topical antifungal drugs for the treatment of AD. We searched prominent databases such as EMBASE, PubMed, Cochrane Library, China Biomedical Literature Database
-
Alopecia areata induced by Adalimumab in a patient with Crohn's disease. Dermatol. Ther. (IF 3.7) Pub Date : 2022-11-15 Gianluca Esposito,Serena Spennato,Luigi Guerriero,Federica Ruggiero,Angela Patrì,Gabriella Fabbrocini,Francesca Nastro
-
Step by step surgery for hidradenitis suppurativa. Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-25 Adriana Di Guida,Patrizia Forgione,Luigi Fornaro,Dario Marasca,Gabriella Fabbrocini,Claudio Marasca
-
Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real-life study. Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-19 Angelo Ruggiero,Luca Potestio,Sara Cacciapuoti,Lucia Gallo,Teresa Battista,Elisa Camela,Gabriella Fabbrocini,Matteo Megna
-
New onset of palmoplantar keratosis triggered by COVID-19 vaccination. Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-19 Chisato Itabashi,Kentaro Ohuchi,Yuna Roh,Yoshihide Asano,Taku Fujimura
-
Successful treatment with ustekinumab in CARD14-associated papulosquamous eruption in a Brazilian child Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-14 Ana Elisa Kiszewski, Hiram Larangeira De Almeida Jr
CARD14-associated papulosquamous eruption (CAPE) was proposed in 2018 to describe the clinical features of psoriasis and pityriasis rubra pilaris with CARD 14 mutations. We report a 5-month-old female infant who developed CAPE-associated erythroderma. Although she did not respond to conventional therapies, she responded well to ustekinumab treatment at the age of 4 years.
-
Local hyperthermia as a good treatment option for hands and feet warts in children: Case series report. Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-21 Tingting Wang,Weifang Zhou,Xiaoyong Man,Wei Li
-
Tapinarof for the treatment of psoriasis Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-13 Sofia Nogueira, Maria Alexandra Rodrigues, Ron Vender, Tiago Torres
Although topical drugs are the mainstay of treatment for patients with mild-to-moderate psoriasis, the developments observed in this field in the last two decades have been limited. The most commonly used drugs are still vitamin D analogues and corticosteroids, both with several limitations. The aryl hydrocarbon receptor (AhR) plays a role in the pathogenesis of psoriasis, and tapinarof, a novel, first-in-class
-
Update of pathophysiology and treatment options of seborrheic keratosis Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-13 Surajit Gorai, Shahzaib Ahmad, Syeda Sadia Masood Raza, Hadin Darain Khan, Muhammad Asad Raza, Farshid Etaee, Clay J. Cockerell, Zoe Apalla, Mohamad Goldust
Seborrheic keratosis (SK) is a common, benign tumor that can occur on everybody site and can be conservatively managed. Cosmetic concerns, especially when a lesion involves the facial area, are the most common reason for excision. SK shows male gender preponderance and increasing age is an independent association with the condition. Even though more prevalent in the elderly, it has also been reported
-
Efficacy of oral tofacitinib in refractory chronic spontaneous urticaria and urticarial vasculitis Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-13 Parvin Mansouri, Nikoo Mozafari, Reza Chalangari, Katalin Martits-Chalangari
The treatment of chronic urticaria (CU) is difficult, currently, antihistamines (AH) are the mainstay of treatment, however, up to 40% of patients do not respond to even high (four-fold) daily doses of AH. Tofacitinib is, a small-molecule that blocks JAK1/3 and inhibits intracellular signaling of multiple key cytokines involved in the inflammatory cascade and its beneficial effects were reported in
-
Intralesional combined furosemide and digoxin in cutaneous warts treatment: A randomized controlled clinical trial Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-13 Amira Reda Lofty, Asmaa Mohamed Elbakry, Ghada Abdel Badea Omar, Mervat Hamdino
Although being a benign lesion, Warts can affect the quality of life by causing discomfort, disfigurement, and social embarrassment besides the tendency to spread. Cutaneous wart treatment faces many challenges as the development of an antiviral drug that can eradicate the human papilloma virus (HPV) is difficult. This clinical study aimed to assess the efficacy and safety of intralesional combined
-
Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysis Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-13 Cataldo Patruno, Luca Potestio, Gabriella Fabbrocini, Maddalena Napolitano
Strategies on long-term management of patients affected by atopic dermatitis (AD) undergoing treatment with dupilumab achieving good clinical response (GCR) or experiencing dupilumab-related adverse events (AEs) are scant. Data of patients who implemented longer than scheduled dupilumab dosing interval due to GCR (at least 52 weeks of treatment and controlled AD activity [Eczema Area Severity Index
-
COVID-19 vaccine-related eruption of papules and plaques-A case report. Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-21 Aylin Kafelova,Valeria Mateeva,Jana Kazandjieva,Lyubka Miteva,Lyubomir Dourmishev
-
Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-12 Zhu-Han He, Shuo-Cheng Qiu, Zhi-Wei Huang, Guo-Qiang Zhang, Qing-Qing An, Feng Qu, Na Wang
This meta-analysis aimed to assess the efficacy of omalizumab in the treatment of refractory-to-antihistamines chronic induced urticaria (CIndU) in comparison with that of refractory-to-antihistamines chronic spontaneous urticaria (CSU). We retrieved interventional studies and observational studies on omalizumab efficacy to CIndU patients and efficacy comparison between CSU and CIndU both refractory
-
Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-12 Pablo Chicharro, Mar Llamas-Velasco, Susana Armesto, Enrique Herrera Acosta, David Vidal, Eva Vilarrasa, Raquel Rivera-Diaz, Pablo De-la-Cueva, Antonio Martorell-Calatayud, Ferran Ballescà, Isabel Belinchon, Gregorio Carretero, Lourdes Rodriguez, Alberto Romero-Maté, Josep Pujol-Montcusí, Laura Salgado, Antonio Sahuquillo-Torralba, Pablo Coto-Segura, Ofelia Baniandrés Rodríguez, Rosa Feltes, José Riera-Monroig
The aim of the study was to assess the long-term effectiveness and safety of secukinumab in Spanish patients with moderate-to-severe psoriasis in a daily practice setting. Nationwide multicenter, observational, retrospective, non-interventional, single-cohort study including patients who initiated treatment with secukinumab in daily clinical practice conditions. Subjects were followed for a minimum
-
Rapid response of recalcitrant linear IgA bullous dermatosis to omalizumab: A case report and literature review. Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-27 Xin Tong,Long Geng,Xing-Hua Gao,Hong-Hui Xu
-
Treatment of acquired reactive perforating collagenosis with dupilumab in a patient with end-stage renal disease. Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-17 Yu Jin Lee,June Hyunkyung Lee,Jae Eun Choi,Tae Young Han
-
The impact of face masks on acne-prone skin in Polish young adults during COVID-19 pandemic Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-11 Stanisław Anczyk, Maciej Stępień, Michał Raczyński, Adam Anczyk, Maja Woźniakowska, Bartosz Miziołek, Karina Polak, Beata Bergler-Czop
COVID-19 pandemic raised many problems for patients with acne-prone skin: a limited access to health care services, the necessity of developing telemedical consultations also in dermatology, and the usage of face masks. The aim of the study was to investigate the influence of respiratory protective measures (type of masks, wearing time during the day) on declared skin condition in patients already
-
Atypical presentation of Sweet syndrome with nodular erythema and oral ulcerations provoked by Ad26.COV2.S SARS-CoV-2 vaccination and review of literature Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-11 Agata Bechtold, Agnieszka Owczarczyk-Saczonek
The aim of this article is to present the case of acute febrile neutrophilic dermatosis (Sweet syndrome—SS) after Ad26.COV2.S vaccination against SARS-CoV-2. To the best of our knowledge, this is the second case of SS provoked by this specific vaccine. What is more, the mildly symptomatic beginning of the disease, later followed by typical SS manifestation with a variety of symptoms including nodular
-
Which is more effective in atrophic acne scars treatment microneedling alone or platelet rich plasma alone or combined both therapeutic modalities? Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-11 Sahar A. Ismail, Nanis A. H. Khella, Doaa A. E. Abou-Taleb
Acne scarring usually causes cosmetic and psychological problems. Our aim of the study was to compare the efficacy of microneedling alone, intradermal injection of platelet rich plasma (PRP) alone and combined microneedling with PRP in the treatment of atrophic post-acne scars. Thirty adult patients with facial post-acne scars were randomly recruited and divided into two groups: A and B. Group A: included
-
Dupilumab: Advances in the off-label usage of IL4/IL13 antagonist in dermatoses Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-11 Fengming Jia, Qing Zhao, Peidian Shi, Hong Liu, Furen Zhang
Type 2 immune response refers to a complicated series of immune responses characterized by Th2 polarization and Th2 cytokines secretion. The IgE secretion, airway hypersensitivity, and effector cell recruitment (eosinophils, mast cells, basophils) in skin lesion and peripheral blood stream could be upregulated during the activation of type 2 immune response. Th1/Th2 ratio, also referred as Th1/Th2
-
Reactive perforating collagenosis treated with dupilumab: A case report and literature review. Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-21 Lan Guo,Yue-Ping Zeng,Hong-Zhong Jin
-
Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of nail psoriasis Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-10 Giuseppe Gallo, Luca Mastorino, Diego Barilà, Francesco Cattel, Michele Panzone, Pietro Quaglino, Simone Ribero, Paolo Dapavo
Nail psoriasis is a chronic nail disorder that commonly affects psoriatic patients causing severe distress despite the limited body surface area. Treatments for nail psoriasis are limited, as nails are often difficult to treat with topical therapies, and among different systemic agents responses are unpredictable. We carried out a prospective study in order to analyze the effectiveness and tolerability
-
Efficacy of topical steroids in preventing radiation dermatitis: A systematic review and meta-analysis Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-10 Xinyi Shao, Tingqiao Chen, Hao Li, Yangmei Chen, Yujie Zhang, Jiayi Chen, Yuxin Li, Lin Liu, Yihuan Pu, Jin Chen
To evaluate the relative efficacy of topical steroids in preventing radiation dermatitis (RD). Multiple databases including Medline, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), China Biological Medicine (SinoMed), and Wanfang Database were searched for randomized controlled trials (RCTs) of RD prevention in patients with cancer from inception to November
-
Treatment of facial pigmented disorders with a 785-nm picosecond Ti:sapphire laser in Asians: A report of three cases Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-10 Jun Ki Hong, Young Gue Koh, Kapsok Li, Seong Jun Seo, Suk Bae Seo, Kui Young Park
Since the advent of the theory of selective photothermolysis, the importance of targeting the chromophore and minimizing the surrounding damage has been extensively discussed. Picosecond-domain laser (ps-laser) treatment with a wide range of wavelengths is an emerging option for various pigmented lesions; however, no definitive treatment choice has been confirmed. The authors aimed to investigate the
-
Sweet syndrome after the first dose of SARS-CoV-2 vaccine (Pfizer-BioNTech). Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-17 Min Jae Kim,Jee Woo Kim,Jung-Im Na
-
Photodynamic therapy in uncommon forms of lichen planus. Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-17 Miriam Fernández-Parrado,Jorge Arostegui-Aguilar,Héctor Perandones-González,Ingrid Hiltun,Teresa de Dot-Gómara,Mónica Larra-García,Juan Ignacio Yanguas-Bayona
-
Comparative study between topical application of triamcinolone acetonide after fractional carbon dioxide laser versus microneedling in the treatment of resistant alopecia areata Dermatol. Ther. (IF 3.7) Pub Date : 2022-10-09 Mai Mohamed Omar, Zakaria Mahran Obaid, Osama Magdy Elshahat Sayedahmed
Alopecia areata (AA) is a disease that affects the psychological well-being of the affected individuals. Laser-assisted drug delivery and microneedling (MN) are promising methods for the treatment of different dermatological diseases. The aim of the study was to compare the efficacy of topical application of triamcinolone acetonide after fractional carbon dioxide laser versus MN in the treatment of